Section 1 - CHEMICAL PRODUCT AND COMPANY IDENTIFICATION

PRODUCT NAME

JASOL REDIC R2-20-AT

NFPA

PRODUCT USE

The use of a quantity of material in an unventilated or confined space may result in
increased exposure and an irritating atmosphere developing.Before starting consider
control of exposure by mechanical ventilation. Electrical solvent / degreaser.

Section 2 - HAZARDS IDENTIFICATION

CANADIAN WHMIS SYMBOLS

EMERGENCY OVERVIEW

RISK

May form explosive peroxides.
Irritating to skin.
May cause CANCER.
Toxic to aquatic organisms, may cause long- term adverse effects in the aquatic
environment.

POTENTIAL HEALTH EFFECTS

ACUTE HEALTH EFFECTS

SWALLOWED

  Accidental ingestion of the material may be damaging to the health of the individual.  

EYE

  Limited evidence or practical experience suggests, that the material may cause eye irritation in a substantial number of individuals. Prolonged eye contact may cause inflammation characterized by a temporary redness of the conjunctiva (similar to windburn).  Irritation of the eyes may produce a heavy secretion of tears (lachrymation).  The liquid may produce eye discomfort and is capable of causing temporary impairment of vision and/or transient eye inflammation, ulceration.  

SKIN

  Skin contact with the material may damage the health of the individual; systemic effects may result following absorption.  The material may cause moderate inflammation of the skin either following direct contact or after a delay of some time. Repeated exposure can cause contact dermatitis which is characterized by redness, swelling and blistering.  Entry into the blood-stream, through, for example, cuts, abrasions or lesions, may produce systemic injury with harmful effects. Examine the skin prior to the use of the material and ensure that any external damage is suitably protected.  Absorption by skin may readily exceed vapor inhalation exposure. Symptoms for skin absorption are the same as for inhalation.  

INHALED

  Inhalation may produce health damage*.  Inhalation of vapors or aerosols (mists, fumes), generated by the material during the course of normal handling, may be damaging to the health of the individual.  There is some evidence to suggest that the material can cause respiratory irritation in some persons. The body's response to such irritation can cause further lung damage.  Inhalation hazard is increased at higher temperatures.  Inhalation of vapours may cause drowsiness and dizziness. This may be accompanied by narcosis, reduced alertness, loss of reflexes, lack of coordination and vertigo.  Anesthetics and narcotic effects (with dulling of senses and odor fatigue) are a consequence of exposure to chlorinated solvents.  Individual response varies widely; odor may not be considered objectionable at levels which quickly induce central nervous system effects. High vapor concentrations may give a feeling of euphoria. This may result in reduced responses, followed by rapid onset of unconsciousness, possible respiratory arrest and death.  Acute intoxication by halogenated aliphatic hydrocarbons appears to take place over two stages. Signs of a reversible narcosis are evident in the first stage and in the second stage signs of injury to organs may become evident, a single organ alone is (almost) never involved.  The use of a quantity of material in an unventilated or confined space may result in increased exposure and an irritating atmosphere developing.Before starting consider control of exposure by mechanical ventilation.  

CHRONIC HEALTH EFFECTS

  There is ample evidence that this material can be regarded as being able to cause cancer in humans based on experiments and other information.  There is some evidence to provide a presumption that human exposure to the material may result in impaired fertility on the basis of: some evidence in animal studies of impaired fertility in the absence of toxic effects, or evidence of impaired fertility occurring at around the same dose levels as other toxic effects but which is not a secondary non-  specific consequence of other toxic effects.  Halogenated oxiranes may arise following epoxidation of haloalkenes.  The carcinogenicity of halogenated oxiranes may lie in the reactivity of an epoxide intermediate. It is reported that 1,1-dichloroethylene, vinyl chloride, trichloroethylene,  tetrachloroethylene and chloroprene, for example, are carcinogens in vivo - this may be a consequence of oxirane formation.  Symmetrically substituted oxiranes such as 1,2-dichloroethylene and 1,1,2-2-  tetrachloroethylene are more stable and less mutagenic than unsymmetrical chlorinated oxiranes such as 1,1-dichloroethylene, 1,1,2-trichloroethylene and monochloroethylene (vinyl chloride).  The carcinogenicity of 1,1-dichloroethylene has primarily been associated with inhalation exposure while that of vinyl chloride, trichloroethylene and tetrachloroethylene occurs following exposure by both inhalation and oral routes. National Toxicology Program Toxicity Report Series Number 55; April 2002 Various studies report an association between cancer and industrial exposure to tetrachloroethylene; IARC concluded that this evidence is sufficient to assign appropriate warnings. Similar warnings have been issued by IARC for vinyl fluoride. Similarly vinyl bromide exhibited neoplastic and tumourigenic activity in rats exposed by inhalation and is classified by various bodies as potentially carcinogenic.  Substances such as chloroprene (2-chloro-1,3-butadiene), are reported to produce an increased frequency of chromosomal aberrations in the lymphocytes of Russian workers. Russian epidemiological studies also suggest an increased incidence of skin and lung cancer following exposure to chloroprene, a result which is not supported by other studies.  Generally speaking, the monohalogenated substances exhibit higher carcinogenic potential than their dihalogenated counterparts. Whether additional substitution lessens such hazard is conjectural. Tetrafluoroethylene, for example, produced clear evidence of carcinogenic activity in a two-year inhalation study in rats and mice. National Toxicology Program Technical Report Series 450, April 1997.